Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Short Interest Down 6.0% in March

Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) saw a large drop in short interest in the month of March. As of March 31st, there was short interest totalling 22,100 shares, a drop of 6.0% from the March 15th total of 23,500 shares. Approximately 1.2% of the shares of the company are sold short. Based on an average trading volume of 3,000 shares, the short-interest ratio is currently 7.4 days.

Institutional Trading of Cyclerion Therapeutics

Several hedge funds have recently made changes to their positions in the company. Geode Capital Management LLC lifted its stake in shares of Cyclerion Therapeutics by 0.9% in the 1st quarter. Geode Capital Management LLC now owns 592,237 shares of the company’s stock worth $257,000 after acquiring an additional 5,500 shares during the period. Renaissance Technologies LLC lifted its stake in shares of Cyclerion Therapeutics by 50.7% in the 2nd quarter. Renaissance Technologies LLC now owns 456,077 shares of the company’s stock worth $250,000 after acquiring an additional 153,519 shares during the period. Tyndall Capital Partners L P lifted its stake in shares of Cyclerion Therapeutics by 11.3% in the 4th quarter. Tyndall Capital Partners L P now owns 164,429 shares of the company’s stock worth $551,000 after acquiring an additional 16,717 shares during the period. Prelude Capital Management LLC lifted its stake in shares of Cyclerion Therapeutics by 25.9% in the 2nd quarter. Prelude Capital Management LLC now owns 126,192 shares of the company’s stock worth $69,000 after acquiring an additional 25,937 shares during the period. Finally, Jane Street Group LLC acquired a new stake in shares of Cyclerion Therapeutics in the 2nd quarter worth $32,000. Institutional investors and hedge funds own 75.62% of the company’s stock.

Cyclerion Therapeutics Stock Performance

CYCN stock opened at $3.25 on Thursday. Cyclerion Therapeutics has a one year low of $1.75 and a one year high of $7.00. The stock has a market capitalization of $8.81 million, a PE ratio of -0.59 and a beta of 1.84. The company has a fifty day moving average of $3.12 and a 200-day moving average of $3.06.

About Cyclerion Therapeutics

Cyclerion Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is Zagociguat (CY6463), a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's disease with vascular pathology; and Phase 1 trials diagnosed with schizophrenia in adults.